3-碘苯二甲酸 | 6937-34-4

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-碘苯二甲酸
• 中文别名: 3-碘邻苯二甲酸
• 英文名称: 3-iodophthalic acid
• CAS: 6937-34-4
• 化学式: C₈H₅IO₄
• mdl: MFCD00275568
• 分子量: 292.03
• InChiKey: HNPVERUJGFNNRV-UHFFFAOYSA-N

物化性质

• 熔点：
  200-204 °C
• 沸点：
  426.3±40.0 °C(Predicted)
• 密度：
  2.138±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 安全说明：
  S26,S37/39
• 海关编码：
  2917399090
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温下保存，需避光、干燥并密封。

SDS

Name:	3-Iodophthalic acid 95+% Material Safety Data Sheet
Synonym:
CAS:	6937-34-4

Section 1 - Chemical Product MSDS Name:3-Iodophthalic acid 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6937-34-4	3-Iodophthalic acid	95+%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 6937-34-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: tan
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 232 - 236 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H5IO4
Molecular Weight: 292

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, hydrogen iodide, iodine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 6937-34-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Iodophthalic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 6937-34-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 6937-34-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 6937-34-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-碘苯二甲酸 在 organostannatrane compound 、 碳酸氢钠 作用下， 以 水 为溶剂， 以84%的产率得到邻苯二甲酸
  参考文献：
  名称：

  A water soluble, recyclable organostannatrane

  摘要：

  Synthesis of a water-soluble recyclable organostannatrane has been accomplished via a straightforward three-step synthesis. The organostannatrane exhibits excellent water-solubility (0.33 M) and can be recovered from aqueous solutions via removal of water in vacuo. The compound can be readily converted by standard transformations into reagents suitable for Stille cross-coupling reactions. The reagent can also be transformed into a reactive, water-soluble organotin hydride. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(01)01148-0
• 作为产物：
  描述：

  1,2-二甲基-3-碘苯 在 potassium permanganate 、 sodium hydroxide 、 盐酸 作用下， 以 水 为溶剂， 反应 0.08h， 以3.94 g的产率得到3-碘苯二甲酸
  参考文献：
  名称：

  New thalidomide analogues derived through Sonogashira or Suzuki reactions and their TNF expression inhibition profiles

  摘要：

  A library of new thalidomide C4/5 analogues containing either a phenyl or alkyne tether were synthesized using Sonogashira or Suzuki cross coupling reactions from their aryl halogenated precursors. All thalidomide analogues were tested for their ability to inhibit the expression of the proinflammatory cytokine Tumor Necrosis Factor (TNF). More explicitly the use of a novel reporter system utilizing the promoter region of the TNF gene in a human T-cell line provided a rapid and effective measure of NF kappa B transcriptional activity. Several compounds either containing either an aryl-isobutyl or aryl-isopropoxy group were the most effective in inhibiting TNF expression, and were several times more active than thalidomide itself. Five of the more active derivatives indicated an apoptotic response while one of these compounds, containing an aldehyde tether, showed possible influence of cell cycling effects. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.12.001
• 作为试剂：
  描述：

  乙醛酸乙酯 、 1-(4-溴吡啶-2-基)肼 在 3-碘苯二甲酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 2.0h， 以77%的产率得到ethyl 7-bromo-[1,2,4]triazolo[4,3-a]pyridine-3-carboxylate
  参考文献：
  名称：

  取代的杂芳基化合物及其组合物和用途

  摘要：

  本发明公开了取代的杂芳基化合物及其组合物和它们的用途。所述化合物为式(I)所示的化合物或者式(I)所示化合物的立体异构体、互变异构体、氮氧化物、溶剂化物、代谢产物、药学上可接受的盐或它的前药。本发明还提供了包含所述化合物的药物组合物，所述化合物和药物组合物可以调节蛋白激酶，尤其是Aurora激酶和JAK激酶的活性，用于预防、处理、治疗和减轻蛋白激酶，尤其是JAK激酶活性介导的疾病或紊乱。

  公开号：

  CN109776522B

文献信息

• JAK INHIBITOR
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2108642A1

  公开（公告）日：2009-10-14

  A JAK inhibitor comprising, as an active ingredient, a nitrogen-containing heterocyclic compound represented by formula (I) wherein W represents a nitrogen atom or -CH-; X represents -C (=O) - or -CHR4- (wherein R4 represents a hydrogen atom, or the like); R1 represents the formula described below [wherein Q1 represents-CR8-(wherein R8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); Q2 represents -NR15- (wherein R15 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like); and R5 and R6 may be the same or different and each represents a hydrogen atom, halogen, carboxy, substituted or unsubstituted lower alkyl, or the like], or the like; and R2 and R3 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like} or a pharmaceutically acceptable salt thereof.

  一种JAK抑制剂，其作为活性成分的是由式(I)表示的含氮杂环化合物 其中W代表氮原子或-CH-; X代表-C(=O)-或-CHR4-(其中R4代表氢原子或类似物); R1代表下述式[其中Q1代表-CR8-(其中R8代表氢原子、取代或未取代的较低烷基或类似物); Q2代表-NR15-(其中R15代表氢原子、取代或未取代的较低烷基或类似物);而R5和R6可以相同也可以不同，每个代表氢原子、卤素、羧基、取代或未取代的较低烷基或类似物，或类似物;而 R2和R3可以相同也可以不同，每个代表氢原子、卤素、取代或未取代的较低烷基或类似物}或其药学上可接受的盐。
• [EN] OXOINDOLINE DERIVATIVES AS PROTEIN FUNCTION MODULATORS<br/>[FR] DÉRIVÉS D'OXOINDOLINE UTILISÉS COMME MODULATEURS DE LA FONCTION PROTÉIQUE
  申请人：BIOTHERYX INC

  公开号：WO2017201069A1

  公开（公告）日：2017-11-23

  The present invention provides chimeric compounds of formula (II) that modulate protein function, to restore protein homeostasis, including cytokine, aiolos, and/or ikaros activity, TNF-alpha activity, CKl-alpha activity and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions, such as cytokine-mediated diseases, disorders, and conditions, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, organ transplant rejection, and cancer, are provided.

  本发明提供了公式（II）的嵌合化合物，用于调节蛋白功能，恢复蛋白稳态，包括细胞因子、aiolos和/或ikaros活性，TNF-alpha活性，CKl-alpha活性和细胞间黏附。该发明提供了调节蛋白介导疾病的方法，如细胞因子介导的疾病、紊乱、状况或反应。提供了与其他细胞因子和炎症介质结合的组合物。提供了治疗、改善或预防蛋白介导疾病、紊乱和状况的方法，如细胞因子介导的疾病、紊乱和状况，包括炎症、纤维肌痛综合征、类风湿关节炎、骨关节炎、强直性脊柱炎、牛皮癣、银屑病性关节炎、炎症性肠病、克罗恩病、溃疡性结肠炎、葡萄膜炎、炎症性肺部疾病、慢性阻塞性肺疾病、阿尔茨海默病、器官移植排斥反应和癌症。
• [EN] DIARYLSULFONES AS 5-HT2A ANTAGONISTS<br/>[FR] DIARYLSULFONES EMPLOYÉES EN TANT QU'ANTAGONISTES DU RÉCEPTEUR 5-HT2A
  申请人：MERCK SHARP & DOHME

  公开号：WO2006021805A1

  公开（公告）日：2006-03-02

  Compounds of formula (I) are potent and selective antagonists of the human 5-HT2A receptor, and hence useful in treatment of a variety of adverse conditions of the CNS.

  式（I）的化合物是人类5-HT2A受体的强效和选择性拮抗剂，因此在治疗中枢神经系统的各种不良症状中非常有用。
• 一锅法制备3-羟基邻苯二甲酸酐的方法
  申请人：济南轩鸿生物医药有限公司

  公开号：CN105330634A

  公开（公告）日：2016-02-17

  本发明涉及一种一锅法制备3-羟基邻苯二甲酸酐的方法，包括如下步骤，将式I化合物溶于有机溶剂中，在铜盐催化剂存在的碱性条件下，在80～130℃，反应1～8小时，然后加入缩合剂，在100～130℃，反应2～8小时，用纯化试剂提纯后，干燥、过滤，即得3-羟基邻苯二甲酸酐。该方法具有合成路线短、条件温和、操作简单、收率较高等优点，且无需复杂的后处理就可以使HPLC纯度≥95％。本发明具有较大的使用价值和社会经济效益。
• Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
  申请人：——

  公开号：US20030073728A1

  公开（公告）日：2003-04-17

  A combination therapy of at least one FBPase inhibitor and at least one other antidiabetic agent is disclosed.

  揭示了至少一种FBPase抑制剂和至少一种其他抗糖尿病药物的联合治疗。